Oral News and Research

RSS

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

Highmark Foundation’s report documents status of safety net providers to improve health outcomes

Efforts made from a four-year, $4.1 million investment to help safety net providers meet the health care needs of the uninsured are documented in a recent Highmark Foundation report.

24 Aug 2010

Carriage Services announces “Company & Investment Profile” update

Carriage Services, Inc. today announced that it has updated its "Company & Investment Profile,".Carriage's updated Company & Investment Profile includes updated discussions of Carriage's business, operating and growth strategies, historical financial information, financial outlook and more.

24 Aug 2010

Study finds multi-modal hemispheric based program improves participant's educational outcomes

A new ADD/ADHD study found that a multi-modal hemispheric based program significantly improved the participant's educational outcomes. The study, "The Effect of Hemispheric Specific Remediation Strategies on the Academic Performance Outcome of Children With ADD/ADHD," was conducted by a research team including, Gerry Leisman, Robert Melillo, Sharon Thum, Mark Ransom, Michael Orlando, Christopher Tice, and Frederick Carrick. The study appears in the current issue of the International Journal of Adolescent Medicine and Health.

24 Aug 2010

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Precision Antibody™ announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium, an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States.

24 Aug 2010

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).

24 Aug 2010

HHS to offer $32 million to increase health care access for rural Americans

HHS Secretary Kathleen Sebelius announced today more than $32 million in FY 2010 funds to increase access to health care for Americans living in rural areas. The funds reach across seven programs administered by the Office of Rural Health Policy in HHS' Health Resources and Services Administration.

24 Aug 2010

Researchers find medication for diabetes, smoking cessation

The script for two research teams inducted today into the American Chemical Society (ACS) scientific "hall of fame" the ACS Heroes of Chemistry is a tale of two pills. One team invented a medication that helps people with diabetes control their blood sugar levels. The second team invented a medicine that helps people stop smoking, an addiction that experts regard as today's single greatest preventable cause of death worldwide.

23 Aug 2010

Focused Ultrasound Surgery Foundation announces young investigator awards

The Focused Ultrasound Surgery Foundation has announced the availability of ten awards of up to $1,000 for young investigators whose abstracts are selected for oral or poster presentation at the 2nd International Symposium on MR-guided Focused Ultrasound in Washington, D.C. from October 17 to 20, 2010.

20 Aug 2010

Cerulean Pharma to assemble scientific experts at ACS National Meeting symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced it will assemble a group of leading scientific experts at the American Chemical Society's ("ACS") 240th National Meeting & Exposition for a three-day thought leadership summit on the advancement of nanotechnology in the pharmaceutical and diagnostic industries.

20 Aug 2010

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

The Center for Pediatric Dentistry opens in Seattle on September 1, 2010

At today's ribbon cutting ceremony, The Center for Pediatric Dentistry, created to address the growing epidemic of childhood dental disease, announced the grand opening of its facility on September 1, 2010. The Seattle-based institute is the first of its kind in the country, providing pediatric dental care, education for dentists and medical professionals, research, and policy under one roof.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Due to overwhelming response from researchers, a second round of abstract submissions for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound will open on Monday, August 23, 2010, nine days earlier than previously announced. The submission deadline will be moved forward to Monday, September 6, 2010.

19 Aug 2010

Study quantifies risk for gastrointestinal illness due to E. coli bacteria at inland beach

New research shows a clear link between increasing levels of E. coli bacteria in an inland Ohio lake and a greater risk that swimmers in the water will suffer a gastrointestinal illness.

19 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

Serious funding shortfalls jeopardize UNICEF's humanitarian operation in Pakistan

UNICEF warned today that serious funding shortfalls are jeopardizing its humanitarian operation in Pakistan. UNICEF is extremely concerned at the lack of funds for its water and sanitation operation, with millions of children at risk from water-borne diseases.

18 Aug 2010

New research explores effects of radiation on human bone after stereotactic radiosurgery

New research holds promise for the thousands of people whose cancer has spread to their bones.A common treatment for such patients is radiation surgery even though very little is known about radiosurgery's impact on bone strength, says Edmond Richer, associate professor of engineering at Southern Methodist University in Dallas.

18 Aug 2010

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

18 Aug 2010

Oral News and Research

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Highmark Foundation’s report documents status of safety net providers to improve health outcomes

Carriage Services announces “Company & Investment Profile” update

Study finds multi-modal hemispheric based program improves participant's educational outcomes

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

HHS to offer $32 million to increase health care access for rural Americans

Researchers find medication for diabetes, smoking cessation

Focused Ultrasound Surgery Foundation announces young investigator awards

Cerulean Pharma to assemble scientific experts at ACS National Meeting symposium

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

The Center for Pediatric Dentistry opens in Seattle on September 1, 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Study quantifies risk for gastrointestinal illness due to E. coli bacteria at inland beach

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Serious funding shortfalls jeopardize UNICEF's humanitarian operation in Pakistan

New research explores effects of radiation on human bone after stereotactic radiosurgery

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News